Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 comparison of Hui Sheng insulin degludec/insulin aspart versus Ryzodeg in Chinese adults with type 2 diabetes mellitus
ChiCTR2400081416Phase 3Completed
- Sponsor
- Peking University People's Hospital
- Start
- Feb 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin degludec + insulin aspart in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Peking University People's Hospital. Primary endpoints: Change from baseline in HbA1c at week 24 and 12-lead electrocardiogram test. Started Feb 2024; status: completed.
02
Drugs
insulin degludec + insulin aspart
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on ChiCTR2400081416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400081416.